Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-07-04

AUTHORS

Emanuela Palmerini, Eric Lodewijk Staals, Louis Baxter Jones, Davide Maria Donati, Alessandra Longhi, R. Lor Randall

ABSTRACT

Opinion statementDenosumab is a RANK ligand inhibitor approved for the treatment of giant cell tumor of bone. While the role of denosumab in the setting of advanced and unresectable disease is well established, its role in surgically resectable disease is currently under discussion. Several prospective and retrospective series on neoadjuvant therapy in potentially resectable tumor with high morbidity surgery reported a relapse rate of 10–20% after resection and 30–40% after curettage. At the same time, less morbid surgery has obvious clinical advantages for the patient, and several studies have shown the efficacy of denosumab in downgrading of the surgical procedure. Currently, the role of neoadjuvant denosumab in operable GCTB is limited to selected cases in which a diffuse reactive bone formation and peripheral ossification can make an easier surgical procedure, for example, in tumors with a large soft tissue component. A planned resection may become less morbid when preoperative denosumab is administered. Whenever a segmental resection is thought to be indicated at diagnosis, denosumab may be considered in the neoadjuvant setting. A preoperative course of 6 months is considered safe and effective. Two case scenarios are presented and critically discussed. Because of the high recurrence rates after denosumab treatment followed by curettage, we discourage the use of denosumab when curettage is considered feasible. In this setting, a short course of preoperative denosumab (2–6 months) may be considered for highly selected cases, for example in pathological fractures. The role of adjuvant denosumab needs further investigation. Long-term disease control has been reported in case of non-surgical lesions, even after treatment interruption, but there is no consensus on ideal treatment duration and dosage for these scenarios. In all cases, multidisciplinary discussion with oncology, pathologist, radiologist, and surgeons is mandatory. Patient’s comorbidities, dental conditions, and preferences, including family planning, should always be taken into account. More... »

PAGES

68

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11864-020-00766-4

DOI

http://dx.doi.org/10.1007/s11864-020-00766-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1128993115

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32623530


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biopsy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone and Bones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Denosumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Giant Cell Tumor of Bone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Image-Guided Biopsy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteolysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmerini", 
        "givenName": "Emanuela", 
        "id": "sg:person.01210215667.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Staals", 
        "givenName": "Eric Lodewijk", 
        "id": "sg:person.01324444267.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324444267.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dallas Sarcoma Associates, Medical City Dallas, Dallas, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Dallas Sarcoma Associates, Medical City Dallas, Dallas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Louis Baxter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donati", 
        "givenName": "Davide Maria", 
        "id": "sg:person.01202643430.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643430.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Longhi", 
        "givenName": "Alessandra", 
        "id": "sg:person.01167151157.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167151157.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, UC Davis, Sacramento, USA", 
          "id": "http://www.grid.ac/institutes/grid.27860.3b", 
          "name": [
            "Orthopaedic Surgery, UC Davis, Sacramento, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Randall", 
        "givenName": "R. Lor", 
        "id": "sg:person.01277415560.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277415560.15"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12957-016-1034-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045889151", 
          "https://doi.org/10.1186/s12957-016-1034-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00402-019-03167-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112771841", 
          "https://doi.org/10.1007/s00402-019-03167-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-008-0370-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010452938", 
          "https://doi.org/10.1007/s00432-008-0370-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-015-4634-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026452907", 
          "https://doi.org/10.1245/s10434-015-4634-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-07-04", 
    "datePublishedReg": "2020-07-04", 
    "description": "Opinion statementDenosumab is a RANK ligand inhibitor approved for the treatment of giant cell tumor of bone. While the role of denosumab in the setting of advanced and unresectable disease is well established, its role in surgically resectable disease is currently under discussion. Several prospective and retrospective series on neoadjuvant therapy in potentially resectable tumor with high morbidity surgery reported a relapse rate of 10\u201320% after resection and 30\u201340% after curettage. At the same time, less morbid surgery has obvious clinical advantages for the patient, and several studies have shown the efficacy of denosumab in downgrading of the surgical procedure. Currently, the role of neoadjuvant denosumab in operable GCTB is limited to selected cases in which a diffuse reactive bone formation and peripheral ossification can make an easier surgical procedure, for example, in tumors with a large soft tissue component. A planned resection may become less morbid when preoperative denosumab is administered. Whenever a segmental resection is thought to be indicated at diagnosis, denosumab may be considered in the neoadjuvant setting. A preoperative course of 6\u00a0months is considered safe and effective. Two case scenarios are presented and critically discussed. Because of the high recurrence rates after denosumab treatment followed by curettage, we discourage the use of denosumab when curettage is considered feasible. In this setting, a short course of preoperative denosumab (2\u20136\u00a0months) may be considered for highly selected cases, for example in pathological fractures. The role of adjuvant denosumab needs further investigation. Long-term disease control has been reported in case of non-surgical lesions, even after treatment interruption, but there is no consensus on ideal treatment duration and dosage for these scenarios. In all cases, multidisciplinary discussion with oncology, pathologist, radiologist, and surgeons is mandatory. Patient\u2019s comorbidities, dental conditions, and preferences, including family planning, should always be taken into account.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11864-020-00766-4", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1022080", 
        "issn": [
          "1527-2729", 
          "1534-6277"
        ], 
        "name": "Current Treatment Options in Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "giant cell tumor", 
      "preoperative denosumab", 
      "cell tumors", 
      "surgical procedures", 
      "long-term disease control", 
      "large soft tissue component", 
      "role of denosumab", 
      "high morbidity surgery", 
      "less morbid surgery", 
      "efficacy of denosumab", 
      "non-surgical lesions", 
      "ideal treatment duration", 
      "use of denosumab", 
      "RANK ligand inhibitor", 
      "obvious clinical advantages", 
      "high recurrence rate", 
      "reactive bone formation", 
      "soft tissue component", 
      "easy surgical procedure", 
      "unresectable disease", 
      "resectable disease", 
      "resectable tumors", 
      "neoadjuvant denosumab", 
      "peripheral ossification", 
      "neoadjuvant setting", 
      "preoperative course", 
      "adjuvant denosumab", 
      "neoadjuvant therapy", 
      "denosumab treatment", 
      "pathological fractures", 
      "treatment interruption", 
      "patient comorbidities", 
      "relapse rate", 
      "segmental resection", 
      "retrospective series", 
      "morbid surgery", 
      "recurrence rate", 
      "less morbid", 
      "dental conditions", 
      "denosumab", 
      "treatment duration", 
      "multidisciplinary discussion", 
      "clinical advantages", 
      "ligand inhibitor", 
      "curettage", 
      "resection", 
      "disease control", 
      "short course", 
      "tumors", 
      "bone formation", 
      "family planning", 
      "comorbidities", 
      "surgery", 
      "tissue components", 
      "disease", 
      "further investigation", 
      "treatment", 
      "bone", 
      "setting", 
      "patients", 
      "GCTB", 
      "therapy", 
      "lesions", 
      "cases", 
      "morbid", 
      "oncology", 
      "surgeons", 
      "role", 
      "diagnosis", 
      "course", 
      "months", 
      "pathologists", 
      "efficacy", 
      "ossification", 
      "radiologists", 
      "inhibitors", 
      "duration", 
      "dosage", 
      "rate", 
      "fractures", 
      "procedure", 
      "case scenario", 
      "interruption", 
      "consensus", 
      "control", 
      "study", 
      "use", 
      "downgrading", 
      "time", 
      "investigation", 
      "series", 
      "discussion", 
      "preferences", 
      "same time", 
      "planning", 
      "components", 
      "conditions", 
      "formation", 
      "advantages", 
      "account", 
      "scenarios", 
      "example"
    ], 
    "name": "Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone", 
    "pagination": "68", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1128993115"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11864-020-00766-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32623530"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11864-020-00766-4", 
      "https://app.dimensions.ai/details/publication/pub.1128993115"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_867.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11864-020-00766-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-00766-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-00766-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-00766-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-00766-4'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      21 PREDICATES      145 URIs      133 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11864-020-00766-4 schema:about N0976e8da430a4ecca52305cb2a1f9896
2 N0dc7fe9fe83042979224b3a6920893e2
3 N3615df59e556412d8b8ca3690feba7ad
4 N40eaf83c88ee4243af569f5f56adfa9a
5 N47ed4d905c9e4cef883195cf62d87dcd
6 N50740b937f1c42e2aee5009887753d03
7 N62c388aeef6f42628e67442b707baba2
8 Na63ab1c0bc02415bbc4dc43d73cc9e58
9 Na895ce916d7c4f15bfc1a516565ce690
10 Na94a940c04004be3920009412d0101f4
11 Nb159a4f0577d4724a116968d7b89edf6
12 Nc0ec5e38c5b147d49d17978a47f81093
13 Nc4f775eaff344653ab411db4addc801a
14 Ncfb8c3dfe64b423fa2ba0befa51c8167
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N695e7b2501d241a2bd8c4688acc09b37
18 schema:citation sg:pub.10.1007/s00402-019-03167-x
19 sg:pub.10.1007/s00432-008-0370-x
20 sg:pub.10.1186/s12957-016-1034-y
21 sg:pub.10.1245/s10434-015-4634-9
22 schema:datePublished 2020-07-04
23 schema:datePublishedReg 2020-07-04
24 schema:description Opinion statementDenosumab is a RANK ligand inhibitor approved for the treatment of giant cell tumor of bone. While the role of denosumab in the setting of advanced and unresectable disease is well established, its role in surgically resectable disease is currently under discussion. Several prospective and retrospective series on neoadjuvant therapy in potentially resectable tumor with high morbidity surgery reported a relapse rate of 10–20% after resection and 30–40% after curettage. At the same time, less morbid surgery has obvious clinical advantages for the patient, and several studies have shown the efficacy of denosumab in downgrading of the surgical procedure. Currently, the role of neoadjuvant denosumab in operable GCTB is limited to selected cases in which a diffuse reactive bone formation and peripheral ossification can make an easier surgical procedure, for example, in tumors with a large soft tissue component. A planned resection may become less morbid when preoperative denosumab is administered. Whenever a segmental resection is thought to be indicated at diagnosis, denosumab may be considered in the neoadjuvant setting. A preoperative course of 6 months is considered safe and effective. Two case scenarios are presented and critically discussed. Because of the high recurrence rates after denosumab treatment followed by curettage, we discourage the use of denosumab when curettage is considered feasible. In this setting, a short course of preoperative denosumab (2–6 months) may be considered for highly selected cases, for example in pathological fractures. The role of adjuvant denosumab needs further investigation. Long-term disease control has been reported in case of non-surgical lesions, even after treatment interruption, but there is no consensus on ideal treatment duration and dosage for these scenarios. In all cases, multidisciplinary discussion with oncology, pathologist, radiologist, and surgeons is mandatory. Patient’s comorbidities, dental conditions, and preferences, including family planning, should always be taken into account.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N68a177d12be541948cfba0c83ee74a32
28 N93e471c17c174bbeb9ca64c74afd1276
29 sg:journal.1022080
30 schema:keywords GCTB
31 RANK ligand inhibitor
32 account
33 adjuvant denosumab
34 advantages
35 bone
36 bone formation
37 case scenario
38 cases
39 cell tumors
40 clinical advantages
41 comorbidities
42 components
43 conditions
44 consensus
45 control
46 course
47 curettage
48 denosumab
49 denosumab treatment
50 dental conditions
51 diagnosis
52 discussion
53 disease
54 disease control
55 dosage
56 downgrading
57 duration
58 easy surgical procedure
59 efficacy
60 efficacy of denosumab
61 example
62 family planning
63 formation
64 fractures
65 further investigation
66 giant cell tumor
67 high morbidity surgery
68 high recurrence rate
69 ideal treatment duration
70 inhibitors
71 interruption
72 investigation
73 large soft tissue component
74 lesions
75 less morbid
76 less morbid surgery
77 ligand inhibitor
78 long-term disease control
79 months
80 morbid
81 morbid surgery
82 multidisciplinary discussion
83 neoadjuvant denosumab
84 neoadjuvant setting
85 neoadjuvant therapy
86 non-surgical lesions
87 obvious clinical advantages
88 oncology
89 ossification
90 pathological fractures
91 pathologists
92 patient comorbidities
93 patients
94 peripheral ossification
95 planning
96 preferences
97 preoperative course
98 preoperative denosumab
99 procedure
100 radiologists
101 rate
102 reactive bone formation
103 recurrence rate
104 relapse rate
105 resectable disease
106 resectable tumors
107 resection
108 retrospective series
109 role
110 role of denosumab
111 same time
112 scenarios
113 segmental resection
114 series
115 setting
116 short course
117 soft tissue component
118 study
119 surgeons
120 surgery
121 surgical procedures
122 therapy
123 time
124 tissue components
125 treatment
126 treatment duration
127 treatment interruption
128 tumors
129 unresectable disease
130 use
131 use of denosumab
132 schema:name Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone
133 schema:pagination 68
134 schema:productId N73de75e9f1da400d87df81c9d2ea1557
135 Ndeff8298b84c41bf81f32b3f821eb13b
136 Nf0e8863a43ed4045b078da680411f1cd
137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128993115
138 https://doi.org/10.1007/s11864-020-00766-4
139 schema:sdDatePublished 2022-09-02T16:04
140 schema:sdLicense https://scigraph.springernature.com/explorer/license/
141 schema:sdPublisher N34cf85916c904a9ca1bfd2d1f4215f90
142 schema:url https://doi.org/10.1007/s11864-020-00766-4
143 sgo:license sg:explorer/license/
144 sgo:sdDataset articles
145 rdf:type schema:ScholarlyArticle
146 N0976e8da430a4ecca52305cb2a1f9896 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Radiography
148 rdf:type schema:DefinedTerm
149 N0dc7fe9fe83042979224b3a6920893e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Giant Cell Tumor of Bone
151 rdf:type schema:DefinedTerm
152 N34cf85916c904a9ca1bfd2d1f4215f90 schema:name Springer Nature - SN SciGraph project
153 rdf:type schema:Organization
154 N3615df59e556412d8b8ca3690feba7ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Middle Aged
156 rdf:type schema:DefinedTerm
157 N40eaf83c88ee4243af569f5f56adfa9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Bone Density Conservation Agents
159 rdf:type schema:DefinedTerm
160 N47ed4d905c9e4cef883195cf62d87dcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Humans
162 rdf:type schema:DefinedTerm
163 N4959a422d0ff4903b0b95ff28bc94f4d schema:affiliation grid-institutes:None
164 schema:familyName Jones
165 schema:givenName Louis Baxter
166 rdf:type schema:Person
167 N50740b937f1c42e2aee5009887753d03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Bone Neoplasms
169 rdf:type schema:DefinedTerm
170 N62c388aeef6f42628e67442b707baba2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Image-Guided Biopsy
172 rdf:type schema:DefinedTerm
173 N68a177d12be541948cfba0c83ee74a32 schema:issueNumber 8
174 rdf:type schema:PublicationIssue
175 N695e7b2501d241a2bd8c4688acc09b37 rdf:first sg:person.01210215667.35
176 rdf:rest Na892125fd0874a6eb407297f31306a89
177 N73de75e9f1da400d87df81c9d2ea1557 schema:name doi
178 schema:value 10.1007/s11864-020-00766-4
179 rdf:type schema:PropertyValue
180 N757ff2ce614b46aba744bccc5bccf8d2 rdf:first N4959a422d0ff4903b0b95ff28bc94f4d
181 rdf:rest N951df074675b4e7289349e6e0269107d
182 N8b837b35b9ba4d48ade7906fbc16b4e3 rdf:first sg:person.01277415560.15
183 rdf:rest rdf:nil
184 N93e471c17c174bbeb9ca64c74afd1276 schema:volumeNumber 21
185 rdf:type schema:PublicationVolume
186 N951df074675b4e7289349e6e0269107d rdf:first sg:person.01202643430.41
187 rdf:rest Na23ad17ad67d4d9b8b9a6b82c25a4b1f
188 Na23ad17ad67d4d9b8b9a6b82c25a4b1f rdf:first sg:person.01167151157.23
189 rdf:rest N8b837b35b9ba4d48ade7906fbc16b4e3
190 Na63ab1c0bc02415bbc4dc43d73cc9e58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Osteolysis
192 rdf:type schema:DefinedTerm
193 Na892125fd0874a6eb407297f31306a89 rdf:first sg:person.01324444267.96
194 rdf:rest N757ff2ce614b46aba744bccc5bccf8d2
195 Na895ce916d7c4f15bfc1a516565ce690 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Tomography, X-Ray Computed
197 rdf:type schema:DefinedTerm
198 Na94a940c04004be3920009412d0101f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Bone and Bones
200 rdf:type schema:DefinedTerm
201 Nb159a4f0577d4724a116968d7b89edf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Female
203 rdf:type schema:DefinedTerm
204 Nc0ec5e38c5b147d49d17978a47f81093 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Denosumab
206 rdf:type schema:DefinedTerm
207 Nc4f775eaff344653ab411db4addc801a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Biopsy
209 rdf:type schema:DefinedTerm
210 Ncfb8c3dfe64b423fa2ba0befa51c8167 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Neoadjuvant Therapy
212 rdf:type schema:DefinedTerm
213 Ndeff8298b84c41bf81f32b3f821eb13b schema:name dimensions_id
214 schema:value pub.1128993115
215 rdf:type schema:PropertyValue
216 Nf0e8863a43ed4045b078da680411f1cd schema:name pubmed_id
217 schema:value 32623530
218 rdf:type schema:PropertyValue
219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
220 schema:name Medical and Health Sciences
221 rdf:type schema:DefinedTerm
222 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
223 schema:name Clinical Sciences
224 rdf:type schema:DefinedTerm
225 sg:journal.1022080 schema:issn 1527-2729
226 1534-6277
227 schema:name Current Treatment Options in Oncology
228 schema:publisher Springer Nature
229 rdf:type schema:Periodical
230 sg:person.01167151157.23 schema:affiliation grid-institutes:grid.419038.7
231 schema:familyName Longhi
232 schema:givenName Alessandra
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167151157.23
234 rdf:type schema:Person
235 sg:person.01202643430.41 schema:affiliation grid-institutes:grid.419038.7
236 schema:familyName Donati
237 schema:givenName Davide Maria
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643430.41
239 rdf:type schema:Person
240 sg:person.01210215667.35 schema:affiliation grid-institutes:grid.419038.7
241 schema:familyName Palmerini
242 schema:givenName Emanuela
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35
244 rdf:type schema:Person
245 sg:person.01277415560.15 schema:affiliation grid-institutes:grid.27860.3b
246 schema:familyName Randall
247 schema:givenName R. Lor
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277415560.15
249 rdf:type schema:Person
250 sg:person.01324444267.96 schema:affiliation grid-institutes:grid.419038.7
251 schema:familyName Staals
252 schema:givenName Eric Lodewijk
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324444267.96
254 rdf:type schema:Person
255 sg:pub.10.1007/s00402-019-03167-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1112771841
256 https://doi.org/10.1007/s00402-019-03167-x
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s00432-008-0370-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010452938
259 https://doi.org/10.1007/s00432-008-0370-x
260 rdf:type schema:CreativeWork
261 sg:pub.10.1186/s12957-016-1034-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1045889151
262 https://doi.org/10.1186/s12957-016-1034-y
263 rdf:type schema:CreativeWork
264 sg:pub.10.1245/s10434-015-4634-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026452907
265 https://doi.org/10.1245/s10434-015-4634-9
266 rdf:type schema:CreativeWork
267 grid-institutes:None schema:alternateName Dallas Sarcoma Associates, Medical City Dallas, Dallas, USA
268 schema:name Dallas Sarcoma Associates, Medical City Dallas, Dallas, USA
269 rdf:type schema:Organization
270 grid-institutes:grid.27860.3b schema:alternateName Orthopaedic Surgery, UC Davis, Sacramento, USA
271 schema:name Orthopaedic Surgery, UC Davis, Sacramento, USA
272 rdf:type schema:Organization
273 grid-institutes:grid.419038.7 schema:alternateName Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
274 Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
275 schema:name Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
276 Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...